Impressive Vertex hepatitis C drug data unveiled
November 1, 2008 - A closely watched hepatitis C treatment being developed by Vertex Pharmaceuticals Inc showed an impressive ability to knock out the virus in patients who failed other treatments and those not previously treated for the serious liver disease, data from mid-stage studies show.
U.S. drug industry group defends price of Gilead hepatitis drug
April 10, 2014 — WASHINGTON (Reuters) - The leading U.S. pharmaceutical
industry trade group on Thursday defended the cost of Gilead
Sciences Inc's new hepatitis C drug, Sovaldi, saying such
treatments offer a priceless breakthrough for patients with the
Diabetics' expenses have decreased, but are still high
April 9, 2014 — NEW YORK (Reuters Health) - Out-of-pocket expenses for
diabetes treatment have gone down for many U.S. patients over
the past decade, according to a new study. But nearly a quarter
of people with diabetes still face high expenses.
Women with eating disorders may have more pregnancy complications
April 9, 2014 — NEW YORK (Reuters Health) - Women with a history of eating
disorders were at higher risk of a range of pregnancy-related
complications, a new study from Finland found.
Select news items provided by Reuters Health